Chinese PLA General Hospital: Lymphoma trials

The registry lists 33 Lymphoma studies with Chinese PLA General Hospital as lead sponsor. 18 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 22Phase 2 27Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell LymphomaNot yet recruitingNCT07670260Early Phase 1
• GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ LymphomaRecruitingNCT07138547Phase 1/2
• TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell LymphomaRecruitingNCT06323525Phase 1/2
• Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHLRecruitingNCT06321289Phase 1/2
• TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHLRecruitingNCT06014073Phase 1/2
• CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory LymphomaRecruitingNCT05948033Phase 1/2
• SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT05896046Phase 1/2
• Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell LymphomaRecruitingNCT05833893Phase 2
• Decitabine and Anti-PD-1 in R/R DLBCLRecruitingNCT05816746Phase 2
• TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHLRecruitingNCT05631912Phase 1/2
• Combination of CAR-DC Vaccine and ICIs in Malignant TumorsRecruitingNCT05631886Phase 1
• Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
• IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
• The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
• Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell LymphomasRecruitingNCT04407741Phase 1/2
• Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingNCT04337606Phase 1/2
• Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
• SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
• Atrial Fibrillation Monitoring on Patients With Lymphoma After ChemotherapyStatus unknownNCT05454878
• Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's LymphomaStatus unknownNCT04897477Phase 1/2
• An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or LymphomaStatus unknownNCT04873440Phase 1/2
• Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
• Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04163302Phase 2
• Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04012892Phase 1
• A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or LymphomasStatus unknownNCT03991559Phase 1
• A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
• Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
• A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
• CART-19 Immunotherapy in Mantle Cell LymphomaStatus unknownNCT02081937Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
• Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2